Clinical trial
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
NCT00020969 · CTI BioPharma, Industry · Terminated
Key facts
| NCT number | NCT00020969 |
|---|---|
| Title | Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes |
| Official title | Phase Two Multicenter Study Of Arsenic Trioxide In Patients With Myelodysplastic Syndromes |
| Lead sponsor | CTI BioPharma, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Start date | Mar 1, 2001 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 5, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: